Subcutaneous T-Cell Lymphoma Panniculitis-Like: Complete Guide for ICD-11 Coding

1. Introduction

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) represents a rare and specific form of primary cutaneous lymphoma that presents significant diagnostic challenges for healthcare professionals. This alpha/beta T-cell neoplasm, predominantly CD8+, is characterized by its primary confinement to subcutaneous tissue, manifesting clinically through subcutaneous nodules that characteristically do not present with ulceration.

The clinical importance of this condition lies not only in its rarity, but primarily in the need for precise differentiation from other panniculitides, both inflammatory and neoplastic. SPTCL represents approximately 1% of all primary cutaneous lymphomas, making it an entity that, although uncommon, requires appropriate recognition to ensure appropriate treatment and correct prognosis.

The impact on public health, despite low prevalence, is significant due to potential systemic complications associated, particularly hemophagocytic syndrome, which can be fatal if not recognized early. The nonspecific clinical presentation frequently leads to diagnostic delays, with patients initially being treated for benign panniculitides or other dermatological conditions.

Correct coding using the ICD-11 system is absolutely critical for multiple reasons: it enables appropriate epidemiological tracking of this rare condition, facilitates multicenter clinical studies, ensures appropriate reimbursement for specialized treatments, and guarantees that patients are directed to centers with expertise in cutaneous lymphomas. Furthermore, precise documentation through appropriate coding is essential for monitoring clinical outcomes and development of specific therapeutic protocols for this particular entity.

2. Correct ICD-11 Code

Code: 2B00

Description: Subcutaneous panniculitis-like T-cell lymphoma

Parent category: Mature T-cell or NK-cell lymphomas and lymphoproliferative disorders, primary cutaneous types specified

Official definition: Subcutaneous panniculitis-like T-cell lymphoma is a neoplasm of alpha/beta cells, usually CD8+ T cells, mainly confined to the subcutaneous tissue, presenting clinically as subcutaneous nodules, usually non-ulcerated.

This specific code in the ICD-11 system represents a significant advance in the classification of cutaneous lymphomas, providing greater diagnostic precision compared to previous systems. The hierarchical structure of ICD-11 positions SPTCL appropriately within the spectrum of primary cutaneous T-cell lymphomas, reflecting its distinct nature and unique clinicopathological characteristics.

The correct use of this code requires clear understanding of the diagnostic criteria established by the World Health Organization (WHO) and the European Organization for Research and Treatment of Cancer (EORTC). It is essential that the code be applied only when there is adequate histopathological and immunophenotypic confirmation, demonstrating the characteristic pattern of subcutaneous infiltration by CD8+ alpha/beta T cells, with adipocytic rimming phenomenon and absence of significant epidermal or dermal involvement.

3. When to Use This Code

Scenario 1: Recurrent Subcutaneous Nodules with Histological Confirmation

Patient presenting with multiple subcutaneous nodules in lower and/or upper extremities, with deep biopsy demonstrating atypical lymphocytic infiltrate confined to subcutaneous tissue, with CD8+ positive T cells, CD4 negative, betaF1 expression (confirming alpha/beta T cell receptor), and presence of characteristic adipocytic rimming. Immunohistochemistry confirms absence of gamma/delta T cell markers and absence of CD56 expression.

Scenario 2: Refractory Panniculitis with Cytotoxic Phenotype

Patient with history of clinically diagnosed panniculitis, unresponsive to conventional anti-inflammatory treatments, where subsequent biopsy reveals clonal proliferation of T cells with cytotoxic phenotype (CD8+, TIA-1+, granzyme B+, perforin+), confined predominantly to the subcutaneous tissue, without evidence of epidermal or superficial dermal involvement. T cell receptor rearrangement analysis confirms clonality.

Scenario 3: Presentation with Associated Systemic Symptoms

Patient presenting with subcutaneous nodules accompanied by systemic symptoms such as fever, fatigue, weight loss, and cytopenias, where investigation reveals hemophagocytosis in bone marrow. Skin biopsy demonstrates subcutaneous infiltrate of CD8+ T cells with atypical cytological features, confirming SPTCL as underlying cause of secondary hemophagocytic syndrome.

Scenario 4: Isolated Subcutaneous Lesions without Lymph Node Involvement

Patient with well-defined subcutaneous lesion or lesions, where complete staging (including computed tomography, magnetic resonance imaging, and/or positron emission tomography) demonstrates disease confined to skin and subcutaneous tissue, without lymph node, splenic, or bone marrow involvement. Histology confirms characteristic pattern of SPTCL with CD8+ alpha/beta T cells.

Scenario 5: Differential Diagnosis with Lupus Profundus

Patient initially investigated for lupus profundus due to subcutaneous nodules, but with negative serology for autoantibodies and biopsy demonstrating atypical lymphocytic population with immunophenotyping confirming clonal CD8+ T cells, expression of cytotoxic markers, and infiltration pattern characteristic of SPTCL, without evidence of vasculitis or fibrinoid necrosis typical of lupus.

Scenario 6: Recurrence After Initial Remission

Patient previously diagnosed and treated for SPTCL, presenting with new subcutaneous lesion or lesions after period of remission, where biopsy confirms recurrence of neoplasia with histological and immunophenotypic features identical to original diagnosis, maintaining the pattern of alpha/beta CD8+ T cells confined to subcutaneous tissue.

4. When NOT to Use This Code

Gamma/Delta T-Cell Lymphoma Panniculitis Type

Do not use code 2B00 when immunohistochemical analysis demonstrates expression of gamma/delta T-cell receptors (positive for TCR gamma/delta and negative for betaF1). This variant, previously considered part of the SPTCL spectrum, represents a distinct entity with significantly more unfavorable prognosis and more aggressive clinical behavior. These cases frequently present with CD56 expression and demonstrate cytotoxic phenotype, but must be coded separately due to fundamental biological differences.

Benign Inflammatory Panniculitis

Code 2B00 should not be applied in cases of lupus panniculitis, pancreatic panniculitis, erythema nodosum, or other inflammatory panniculitis, even when they present with prominent lymphocytic infiltrate. The absence of significant cytologic atypia, absence of clonality on molecular analysis, and presence of histologic features specific to each inflammatory condition should direct toward appropriate codes for inflammatory cutaneous diseases.

Cutaneous Lymphomas with Secondary Subcutaneous Involvement

When there is evidence of lymphoma primarily dermal or epidermal with secondary extension to the subcutaneous tissue, specific codes for those entities should be used. For example, mycosis fungoides in advanced stage may involve subcutaneous tissue, but the appropriate code would be 2B01, not 2B00, as the origin and primary pattern of involvement differ fundamentally.

Post-Transplant Lymphoproliferative Disorders

Lymphoproliferative disorders occurring in the context of post-transplant immunosuppression, even when presenting with predominant subcutaneous involvement, require specific coding for immunosuppression-related lymphoproliferative processes, and use of code 2B00 is not appropriate.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The first critical step involves confirming that the diagnosis meets the established criteria for SPTCL. This requires documentation of deep biopsy including adequate subcutaneous tissue, with superficial punch biopsy being insufficient as it does not achieve adequate depth. Histopathological evaluation must demonstrate atypical lymphocytic infiltrate predominantly confined to subcutaneous adipose tissue, with the characteristic rimming pattern (circumferential involvement of adipocytes by atypical lymphocytes).

Immunohistochemistry is absolutely essential and must include: CD3, CD4, CD8, betaF1, TCR gamma/delta, CD56, cytotoxic markers (TIA-1, granzyme B, perforin), and CD30. The expected phenotype for SPTCL is: CD3+, CD8+, CD4-, betaF1+, TCR gamma/delta-, CD56-, with expression of cytotoxic markers. Clonality analysis through T-cell receptor rearrangement studies by PCR or Southern blot provides important additional confirmation.

Necessary diagnostic instruments include: magnetic resonance imaging to assess extent of subcutaneous involvement, computed tomography or PET-CT for systemic staging, complete blood count with evaluation of cytopenias, liver function tests, LDH, and evaluation for hemophagocytic syndrome if systemic symptoms are present.

Step 2: Verify Specifiers

Although code 2B00 does not have formally recognized subtypes in ICD-11, it is important to document relevant clinical features that may impact prognosis and treatment. This includes: number and location of lesions (solitary versus multiple, anatomical distribution), presence or absence of systemic symptoms (fever, weight loss, fatigue), evidence of hemophagocytic syndrome (cytopenias, hyperferritinemia, hypertriglyceridemia), and complete disease staging.

Severity may be stratified based on: localized versus disseminated disease in the subcutaneous tissue, presence of systemic complications, and response to initial treatments. The duration of symptoms before diagnosis should also be documented, as diagnostic delays are common and may impact outcome.

Step 3: Differentiate from Other Codes

Differentiation from 2B01 (Mycosis Fungoides): Mycosis fungoides presents with primary epidermal and dermal involvement, with characteristic progression through patch, plaque, and tumor stages. Even when there is subcutaneous involvement in advanced stages, the clinical history of preceding superficial skin lesions and the histological pattern of epidermotropism clearly distinguish it from the primarily subcutaneous presentation of SPTCL.

Differentiation from 2B02 (Sézary Syndrome): Sézary syndrome represents a T-cell leukemia/lymphoma with mandatory blood involvement, generalized erythroderma, and presence of circulating Sézary cells. The cellular phenotype also differs, being typically CD4+ in Sézary syndrome versus CD8+ in SPTCL. The absence of erythroderma and blood involvement clearly distinguishes these entities.

Differentiation from 2B03 (Primary Cutaneous CD30-positive T-cell Lymphoproliferative Disorders): These conditions, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, are characterized by strong CD30 expression (>75% of tumor cells) and distinct cellular morphology with large anaplastic cells. SPTCL typically does not express CD30 or presents only focal expression, and the cells are predominantly small to medium-sized without anaplastic morphology.

Step 4: Required Documentation

Checklist of Mandatory Information:

Complete anatomopathological report with detailed description of infiltration pattern
Complete immunohistochemical panel with specific results for each marker
Results of clonality studies (PCR for TCR rearrangement)
Photographic documentation of clinical lesions
Reports of imaging studies (MRI, CT, or PET-CT)
Complete blood count and biochemical test results
Complete staging including bone marrow evaluation if indicated
Documentation of systemic symptoms and their chronology
Record of previous treatments if applicable

Appropriate documentation should include clinical narrative describing initial presentation, temporal evolution, detailed physical examination of lesions, and diagnostic reasoning that led to suspicion of SPTCL. Documentation should be sufficiently detailed to justify specific coding and allow review by other professionals or for audit purposes.

6. Complete Practical Example

Clinical Case

A 45-year-old female patient presents to dermatology consultation with a three-month history of painful subcutaneous nodules in bilateral lower extremities. She reports intermittent episodes of low-grade fever and progressive fatigue. Denies significant weight loss. On physical examination, four subcutaneous nodules are identified, two on each thigh, measuring 2-4 cm in diameter, mobile, tender to palpation, without alterations in overlying skin (no erythema, warmth, or ulceration). No palpable lymphadenopathy.

Initially, erythema nodosum was considered as a diagnosis, and the patient was treated with nonsteroidal anti-inflammatory drugs without improvement after four weeks. Due to persistence and progression of lesions (emergence of a new nodule), a deep incisional biopsy of one of the right thigh lesions was performed.

Histopathological examination revealed atypical lymphocytic infiltrate confined to subcutaneous tissue, with a characteristic pattern of involvement of adipose lobules. Prominent adipocytic rimming was observed, with small to medium-sized atypical lymphocytes surrounding individual adipocytes. Areas of fat necrosis and presence of histiocytes with focal hemophagocytosis were noted. The dermis and epidermis were preserved, without evidence of infiltration.

Immunohistochemistry demonstrated: CD3+ (diffuse positive), CD8+ (positive in majority of atypical cells), CD4- (negative), betaF1+ (positive, confirming alpha/beta receptor), TCR gamma/delta- (negative), CD56- (negative), TIA-1+ (positive), granzyme B+ (focal positive), perforin+ (focal positive), CD30- (negative). The Ki-67 proliferative index was approximately 30%.

Molecular studies by PCR confirmed clonal rearrangement of the T cell receptor gene. Complete blood count showed mild anemia (hemoglobin 10.5 g/dL) and borderline leukopenia. LDH was slightly elevated. Serum ferritin was markedly elevated (2500 ng/mL). Triglycerides were increased.

Magnetic resonance imaging of the lower extremities confirmed multiple nodular lesions confined to subcutaneous tissue, without muscular or osseous involvement. Computed tomography of the chest, abdomen, and pelvis revealed no lymphadenopathy or organomegaly. Bone marrow biopsy demonstrated reactive hypercellularity with hemophagocytosis, without evidence of lymphomatous infiltration.

Step-by-Step Coding

Criteria Analysis:

Clinical presentation: Subcutaneous nodules without ulceration - ✓ Compatible
Anatomical location: Confinement to subcutaneous tissue - ✓ Confirmed by histology and imaging
Cellular phenotype: CD3+, CD8+, CD4-, betaF1+, TCR gamma/delta- - ✓ Characteristic pattern of CD8+ alpha/beta T cells
Histological pattern: Adipocytic rimming, lobular infiltrate - ✓ Present
Clonality: Clonal rearrangement of TCR - ✓ Confirmed
Exclusion of variants: Negative for gamma/delta and CD56 - ✓ Excludes gamma/delta variant

Code Selected: 2B00 - Subcutaneous T cell lymphoma panniculitis-like

Complete Justification:

Code 2B00 is appropriate because all established diagnostic criteria for STCL-PL were met. The clinical presentation with non-ulcerated subcutaneous nodules, the histological confirmation of atypical lymphocytic infiltrate confined to subcutaneous tissue with characteristic pattern of adipocytic rimming, and the immunohistochemical phenotype demonstrating CD8+ alpha/beta T cells with cytotoxic markers are diagnostic of this specific entity.

Exclusion of gamma/delta variant is crucial and was confirmed by positivity for betaF1 and negativity for TCR gamma/delta. Absence of epidermal or dermal involvement excludes mycosis fungoides. Absence of circulating cells and erythroderma excludes Sézary syndrome. Negativity for CD30 excludes CD30-positive cutaneous lymphomas.

Complementary Codes:

Code for secondary hemophagocytic syndrome (4A44.1) - due to evidence of hemophagocytosis in bone marrow and laboratory criteria
Code for secondary anemia if clinically significant

7. Related Codes and Differentiation

Within the Same Category

2B01: Mycosis Fungoides

When to use 2B01 vs. 2B00: Mycosis fungoides should be coded when there is evidence of primary involvement of the epidermis and/or dermis, with the characteristic pattern of epidermotropism (migration of atypical lymphocytes to the epidermis). The typical clinical progression through patch (macules), plaque, and tumor stages, with visible superficial cutaneous lesions, clearly distinguishes it from the deep subcutaneous presentation of PCLBCL-LT.

Main difference: Primary anatomical location (epidermal/dermal vs. subcutaneous), cell phenotype (generally CD4+ vs. CD8+), histological pattern (epidermotropism vs. adipocytic rimming), and clinical presentation (superficial cutaneous lesions vs. deep subcutaneous nodules).

2B02: Sézary Syndrome

When to use 2B02 vs. 2B00: Sézary syndrome requires mandatory presence of diagnostic triad: erythroderma (cutaneous involvement >80% of body surface), lymphadenopathy, and presence of circulating Sézary cells in peripheral blood (absolute count ≥1000 cells/mm³ or CD4/CD8 ≥10, or demonstrable clonal population).

Main difference: Mandatory leukemic involvement, generalized erythroderma, CD4+ phenotype, and systemic presentation from onset, contrasting with localized subcutaneous involvement and absence of circulating cells in PCLBCL-LT.

2B03: Primary Cutaneous T-cell Lymphoproliferative Disorders CD30-positive

When to use 2B03 vs. 2B00: This code encompasses lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, conditions characterized by strong CD30 expression in >75% of neoplastic cells. The cell morphology with large, frequently anaplastic cells, and the clinical behavior with lesions that may spontaneously regress (lymphomatoid papulosis) fundamentally differ from PCLBCL-LT.

Main difference: Strong CD30 expression (vs. negative in PCLBCL-LT), large/anaplastic cell morphology (vs. small to medium in PCLBCL-LT), dermal involvement (vs. subcutaneous in PCLBCL-LT), and clinical behavior with potential for spontaneous regression.

Differential Diagnoses

Gamma/Delta T-cell Lymphoma Panniculitis Type: Although histologically similar to PCLBCL-LT, this entity expresses gamma/delta T-cell receptors (TCR gamma/delta+, betaF1-) and frequently CD56. It presents significantly worse prognosis and more aggressive behavior, requiring separate coding.

Lupus Panniculitis (Lupus Erythematosus Profundus): May clinically mimic PCLBCL-LT with subcutaneous nodules, but differs by the presence of lymphocytic vasculitis, fibrinoid necrosis, mucin deposition, and absence of lymphocytic atypia or clonality. Positive serology for antinuclear antibodies and anti-DNA aids in differentiation.

Peripheral T-cell Lymphoma with Cutaneous Involvement: When a nodal T-cell lymphoma presents with secondary cutaneous involvement, coding should reflect the primary nodal origin, not the primary cutaneous lymphoma code.

8. Differences with ICD-10

In the ICD-10 system, subcutaneous T-cell lymphoma panniculitis-like did not have its own specific code, being generally classified under C84.4 (Peripheral cutaneous T-cell lymphoma, unspecified) or C84.8 (Other specified mature T/NK-cell lymphomas). This lack of specificity represented a significant limitation for epidemiological tracking and clinical studies focused on this particular entity.

Closest ICD-10 code: C84.8 - Other specified mature T/NK-cell lymphomas

Main changes in ICD-11:

The introduction of the specific code 2B00 in ICD-11 represents a substantial advance, reflecting the recognition of this entity as a distinct form of primary cutaneous lymphoma with unique clinicopathological characteristics. The improved hierarchical structure in ICD-11 appropriately positions SCLP within the category of primary cutaneous T-cell lymphomas, facilitating differentiation from other related entities.

The clear separation between alpha/beta variant (code 2B00) and gamma/delta variant in ICD-11 reflects modern understanding of the distinct biology and prognosis of these conditions, which were previously often grouped together. This distinction has important therapeutic and prognostic implications.

Practical impact of these changes:

More specific coding allows for more precise collection of epidemiological data on the incidence and prevalence of true SCLP (alpha/beta), facilitating clinical research and development of specific therapeutic guidelines. For health systems, specific coding facilitates appropriate resource allocation and patient referral to specialized centers. For reimbursement purposes, specificity reduces ambiguity and potential disputes related to the appropriateness of specialized treatments.

9. Frequently Asked Questions

How is the definitive diagnosis of SPTCL made?

Definitive diagnosis requires a combination of clinical, histopathological, immunophenotypic, and molecular evaluation. Clinically, the presence of subcutaneous nodules without ulceration raises suspicion. The biopsy should be deep (incisional or excisional), reaching adequate subcutaneous tissue, as superficial punch biopsies are frequently insufficient. Histopathological examination should demonstrate atypical lymphocytic infiltrate confined to the subcutaneous tissue with a characteristic pattern of adipocytic rimming. Immunohistochemistry is essential to confirm CD3+, CD8+, betaF1+ phenotype (alpha/beta T cells), with negativity for CD4, TCR gamma/delta, and CD56. Clonality studies by PCR demonstrating monoclonal T cell receptor rearrangement provide important additional confirmation. Complete staging with imaging studies and laboratory evaluation is necessary to exclude systemic involvement.

Is treatment available in public health systems?

Treatment for SPTCL is generally available in public health systems, although access may vary depending on local infrastructure and availability of specialized oncology and dermatology centers. Therapeutic options range from watchful observation in indolent and localized cases to systemic treatments such as corticosteroids, multiagent chemotherapy, or immunosuppressive therapies. Cases with localized disease may be treated with surgical excision or radiotherapy. Most of these treatments are part of the standard therapeutic arsenal for lymphomas and are available in oncology centers. However, due to the rarity of the condition, referral to tertiary centers with specific expertise in cutaneous lymphomas is frequently necessary to optimize management.

How long does treatment last?

Treatment duration varies significantly depending on disease extent, therapeutic response, and presence of complications. Localized cases treated with surgical excision or radiotherapy may require only the initial procedure followed by surveillance. When systemic treatment is necessary, chemotherapy protocols typically involve multiple cycles over several months (usually 4-6 cycles). Immunosuppressive therapies or corticosteroids may be maintained for prolonged periods depending on response. It is important to emphasize that SPTCL frequently requires long-term monitoring due to the potential for recurrence, even after initial complete response. Follow-up generally includes regular clinical evaluations and periodic imaging studies, potentially extending for years after completion of active treatment.

Can this code be used in medical certificates?

Yes, code 2B00 can and should be used in medical certificates when appropriate, particularly in documentation that requires precise diagnostic specification. For work absence certificates, the use of the ICD-11 code provides objective justification for work incapacity, which may be significant during periods of active treatment or complications such as hemophagocytic syndrome. However, it is important to consider confidentiality issues and, in some jurisdictions, it may be appropriate to use broader categories in documents that will be seen by non-healthcare professionals. For internal medical documentation, reports for health insurers, or communication between professionals, the specific code 2B00 should always be used to ensure diagnostic accuracy.

What is the prognosis of SPTCL?

The prognosis of true SPTCL (CD8+ alpha/beta variant) is generally favorable compared to other cutaneous lymphomas and significantly better than the gamma/delta variant. Studies demonstrate five-year survival rates exceeding 80% for the alpha/beta variant. Factors that influence prognosis include: presence or absence of hemophagocytic syndrome (important negative prognostic factor), disease extent (localized versus disseminated), response to initial treatment, and specific histological characteristics. Development of hemophagocytic syndrome represents a serious complication that requires early recognition and treatment. With appropriate management, including treatment of hemophagocytic syndrome when present, many patients achieve prolonged remission or cure. Long-term follow-up is essential due to the potential for recurrence.

Is there a risk of transformation to more aggressive lymphoma?

True SPTCL (alpha/beta variant) generally does not present with transformation to more aggressive lymphoma, differing from other forms of cutaneous lymphoma such as mycosis fungoides, where transformation to large cell lymphoma can occur. However, it is crucial to differentiate from the outset true SPTCL alpha/beta from the gamma/delta variant, which presents with intrinsically more aggressive behavior. The distinction between these variants through adequate immunohistochemistry (betaF1 vs. TCR gamma/delta) is essential. The main risk in SPTCL alpha/beta is not transformation, but rather development of hemophagocytic syndrome, which can occur in up to 15-20% of cases and represents a medical emergency requiring immediate intensive treatment.

How to differentiate SPTCL from inflammatory panniculitis in clinical practice?

Initial clinical differentiation can be challenging, as both present with subcutaneous nodules. Characteristics suggesting SPTCL include: persistent or progressive lesions despite anti-inflammatory treatment, presence of disproportionate systemic symptoms (fever, weight loss, cytopenias), absence of typical triggering factors for inflammatory panniculitis (trauma, infections, medications), and atypical location. In practice, any panniculitis that does not respond adequately to conservative treatment within 4-6 weeks or that presents with atypical characteristics should undergo deep biopsy for complete histopathological evaluation. The initial biopsy should be sufficiently deep and include adequate tissue for immunohistochemical and molecular studies, as rebiopsies are frequently necessary when the initial biopsy is inadequate.

What are the follow-up care recommendations after treatment?

Follow-up after SPTCL treatment should be structured and long-term. In the first two years after remission, clinical evaluations are recommended every 3-4 months, including complete physical examination with careful palpation of previously affected areas and potential new sites. Periodic laboratory studies (complete blood count, LDH, ferritin) help detect early recurrence or development of hemophagocytic syndrome. Imaging studies (magnetic resonance imaging or PET-CT) are generally performed at 6-12 month intervals in the first years, with decreasing frequency as remission duration increases. After two years without recurrence, the interval between appointments can be gradually extended to 6 months, and subsequently annually. Patients should be counseled about warning signs (new nodules, persistent fever, severe fatigue) that require immediate evaluation, regardless of the scheduled follow-up timeline.

Keywords: subcutaneous lymphoma, panniculitis-like T cell, ICD-11 2B00, primary cutaneous lymphoma, CD8+ T cells, adipocytic rimming, subcutaneous nodules, hemophagocytic syndrome, medical coding, panniculitis differential diagnosis

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Partager